CAH

Cardinal Health, Inc. (CAH) - Fiscal 2025 Form 10-K Summary

Business Context and Reporting Period

This summary covers Cardinal Health, Inc.'s Annual Report on Form 10-K for the fiscal year ended June 30, 2025. Cardinal Health is a global healthcare services and products company operating primarily through two reportable segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD). A third category, Other, includes Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. The company serves hospitals, healthcare systems, pharmacies, and patients in the home.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Consolidated revenue decreased 2% primarily due to the expiration of pharmaceutical distribution contracts with OptumRx in June 2024, which accounted for 17% of fiscal 2024 revenue. This was partially offset by growth in branded and specialty pharmaceutical sales.
• Earnings Growth: GAAP operating earnings surged 83% year-over-year. This increase was significantly driven by a favorable comparison to fiscal 2024, which included a $675 million non-cash goodwill impairment charge related to the GMPD segment. Fiscal 2025 also benefited from $171 million in net litigation recoveries.
• Segment Performance:
  • Pharma: Revenue decreased 3% to $204.6 billion; Segment profit increased 12% to $2.3 billion.
  • GMPD: Revenue increased 2% to $12.6 billion; Segment profit increased 47% to $135 million.
  • Other: Revenue increased 19% to $5.4 billion; Segment profit increased 22% to $516 million.
• Acquisitions: The company deployed $5.3 billion for acquisitions, including Advanced Diabetes Supply Group (ADS) for $1.1 billion, GI Alliance (GIA) for $2.8 billion, and Integrated Oncology Network (ION) for $1.1 billion.

Guidance, Outlook, and Risks

• Capital Deployment: The company expects fiscal 2026 capital expenditures to be approximately $600 million. Dividends were increased to $2.04 per share on an annualized basis. Share repurchases totaled $765 million in fiscal 2025, with $2.7 billion remaining under the current authorization.
• Opioid Litigation: As of June 30, 2025, the company has accrued $4.9 billion related to opioid litigation settlements. Payments of $798 million were made in fiscal 2025, with remaining payments expected through 2038.
• Regulatory and Tax Risks:
  • Tariffs: Recent U.S. tariffs on goods from certain countries could increase sourcing costs and disrupt supply chains.
  • Drug Pricing: An Executive Order on "Most-Favored Nation" prescription drug pricing may impact branded pharmaceutical profitability.
  • Tax Law: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 includes tax reform provisions; the company is evaluating the impact.
• Customer Concentration: CVS Health accounted for 30% of fiscal 2025 revenue. The loss of this customer or other significant contracts could materially impact results.

Investor Verification Checklist

• OptumRx Impact: Verify the extent to which new customer onboarding has offset the revenue loss from the OptumRx contract expiration.
• Acquisition Integration: Monitor the integration progress and profitability contribution of recent MSO acquisitions (GIA, ION, ADS) and the associated amortization costs.
• Opioid Settlement Cash Flow: Track the $4.9 billion accrued liability and the schedule of future payments through 2038 to assess long-term liquidity impact.
• Goodwill Impairment Risk: Review the valuation assumptions for the newly acquired reporting units (Navista & ION, GIA, ADS) given the history of impairments in the GMPD segment.
• Regulatory Changes: Assess the potential financial impact of the new OBBBA tax legislation and the "Most-Favored Nation" drug pricing executive order.